Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>

NCT01614899 is registered in ClinicalTrials.gov with Sumitomo Pharma Co., Ltd. as lead sponsor.

NCT NCT01614899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01614899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>
Lead sponsor
Sumitomo Pharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 2, 2012
Completion date
November 17, 2014
Enrollment
457 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia